<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01911637</url>
  </required_header>
  <id_info>
    <org_study_id>VBY-036-001</org_study_id>
    <nct_id>NCT01911637</nct_id>
  </id_info>
  <brief_title>Safety Study of Single Oral Doses of VBY-036 in Healthy Volunteers (VBY036P1A)</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled, Sequential, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of VBY-036 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virobay Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virobay Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      VBY-036 may treat or prevent nerve pain. This study aims to find the highest safe and
      tolerable single dose of VBY-036 in healthy volunteers. Volunteers are randomly selected to
      receive one dose of either a placebo or VBY-036 (10, 30, 100, 300, 600 or 900 mg).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed description is noted in Brief Summary.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Highest safe and tolerated VBY-036 dose</measure>
    <time_frame>5-days assessment</time_frame>
    <description>Single dose of VBY-036 given one day for each cohort in an ascending manner.
Cohort A1 with 10 mg dose or placebo; Cohort A2 with 30 mg dose or placebo; Cohort A3 with 100 mg dose or placebo; Cohort A4 with 300 mg dose or placebo; Cohort A5 with 600 mg dose or placebo; Cohort A6 with 900 mg dose or placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Confirmation of cathepsin-S inhibition</measure>
    <time_frame>2 days</time_frame>
    <description>Based on the accumulation of Iip 10 and/or cathepsin S protein levels</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The blood level of VBY-036</measure>
    <time_frame>4 days</time_frame>
    <description>The blood level of VBY-036 across the dose range of 10 mg to 900 mg</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>VBY-036</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VBY-036 10 mg, 30 mg, 100 mg, 300 mg, 600 mg, or 900 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VBY-036</intervention_name>
    <description>Study drug VBY-036</description>
    <arm_group_label>VBY-036</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Cathepsin S inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>VBY-036</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 18-60 years old

          -  Screening body mass index between 18-32 kg/m2

          -  Good health, no clinically significant findings in medical history, 12-lead ECG, &amp;
             vital signs;

          -  Clinical lab evaluations (Chem panel [fasted at least 8 hrs], CBC, HbA1c &amp; UA in
             reference range for test lab (unless deemed not clinically significant);

          -  Negative test for drugs of abuse at Screening &amp; at Check-in (includes alcohol);

          -  Negative hepatitis, HIV &amp; TB screens;

          -  Females non-pregnant, non-lactating, &amp; either postmenopausal for at least 1 year,
             surgically sterile for at least 90 days prior to Check-in, or agree to use from the
             time of consent until 90 days after Study Completion an effective form of
             contraception. For all females, a pregnancy test result must be negative at Screening
             &amp; Check-in.

          -  Males will be sterile or agree to use from Check-in until 90 days following discharge
             an effective method of contraception.

          -  Able to comprehend &amp; willing to sign Informed Consent Form

        Exclusion Criteria:

          -  Females pregnant or nursing, or childbearing potential but unwilling to use
             contraception.

          -  History of renal or hepatic impairment; stomach or intestinal surgery or resection,
             malabsorption syndrome, cholecystectomy, or gastro-intestinal dysfunction that would
             alter absorption &amp;/or excretion of orally administered drugs (appendectomy or hernia
             repair allowed);

          -  Anemia (hemoglobin &lt;11.5 g/dL for females; &lt; 13 g/dL for males) or blood donation
             within 8 weeks of Check-in;

          -  Plasma donation within 4 weeks of Check-in;

          -  History of alcoholism or drug addiction within 6 months to Check-in;

          -  Use of drugs of abuse or prescription drugs for recreational use 6 months prior to
             Check-in;

          -  Use of any tobacco-containing or nicotine-containing products 6 months prior to
             Check-in &amp; during study;

          -  Participation in another drug trial 30 days of Check-in (within 8 weeks if previous
             investigational drug has immunomodulary effects, other than cathepsin S inhibition);

          -  History or clinical manifestations of metabolic, hepatic, renal, hematological,
             pulmonary, cardiovascular, gastrointestinal, urological, neurological, or psychiatric
             disorders

          -  History of hypersensitivity or allergies to any drug compound

          -  History or presence of abnormal ECG

          -  Laboratory abnormality deemed clinically significant;

          -  Use of or inability to discontinue any prescription medications/products 14 days prior
             to Check-in &amp; during study;

          -  Use of certain over-the-counter, non-prescription preparations are permitted up to 3
             days before first dose;

          -  Use of alcohol-containing, grapefruit-containing, star fruit containing foods or
             beverages or &quot;energy drinks&quot; 72 hours to Check-in &amp; during study;

          -  Poor peripheral venous access;

          -  Receipt of blood products 6 months to Check-in

          -  Subjects with history of Gilbert's Syndrome;

          -  Strenuous activities 48 hours before receiving experimental or placebo comparator

          -  Illness 5 days to drug administration

          -  Any acute or chronic condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David B. Karpf, MD</last_name>
    <role>Study Director</role>
    <affiliation>Virobay Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Evansville</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2013</study_first_submitted>
  <study_first_submitted_qc>July 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2013</study_first_posted>
  <last_update_submitted>December 27, 2013</last_update_submitted>
  <last_update_submitted_qc>December 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy</keyword>
  <keyword>Subjects</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>VBY-036</keyword>
  <keyword>Maximum</keyword>
  <keyword>Pharmacodynamic</keyword>
  <keyword>Pharmacokinetic</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

